Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

ObsEva SA (OBSEF)

Compare
0.0000
0.0000
(0.00%)
At close: April 14 at 4:00:00 PM EDT
Loading Chart for OBSEF
  • Previous Close 0.0001
  • Open 0.0001
  • Bid --
  • Ask --
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0000 - 0.0100
  • Volume 93,100
  • Avg. Volume 8,199
  • Market Cap (intraday) 154,538
  • Beta (5Y Monthly) 5.95
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

www.obseva.com

15

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OBSEF

View More

Performance Overview: OBSEF

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

OBSEF
0.00%
DAX P (^GDAXI)
6.75%

1-Year Return

OBSEF
99.80%
DAX P (^GDAXI)
17.90%

3-Year Return

OBSEF
900.00%
DAX P (^GDAXI)
50.06%

5-Year Return

OBSEF
900.00%
DAX P (^GDAXI)
106.75%

Compare To: OBSEF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OBSEF

View More

Valuation Measures

Annual
As of 4/14/2025
  • Market Cap

    1.17k

  • Enterprise Value

    1.17k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.00

  • Price/Book (mrq)

    0.00

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    40.34%

  • Return on Assets (ttm)

    10.05%

  • Return on Equity (ttm)

    1,576.52%

  • Revenue (ttm)

    19.64M

  • Net Income Avi to Common (ttm)

    7.92M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.34M

  • Total Debt/Equity (mrq)

    24.32%

  • Levered Free Cash Flow (ttm)

    20.15M

Research Analysis: OBSEF

View More

Company Insights: OBSEF

Research Reports: OBSEF

View More

People Also Watch